• Green Hygienics has launched TruLife Biotech LLC. to focus on the development and advancement of innovative cannabinoid-based nutraceutical and skincare products and brands
• The global industrial hemp market was valued at $5.66 billion in 2020 and is expected to reach a value of $27.72 billion by 2028, growing at a CAGR of 25.17%
• Hemp-derived cannabinoids have been studied for the last 20 years with nothing more than pre-clinical data but the new collaboration with Cinvestav and the creation of TruLife Biotech can help answer these questions and develop the products necessary for ECS deficiencies

Green Hygienics Holdings (OTCQB: GRYN), a California-based tech-driven enterprise focused on the high standard cultivation of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids, recently announced that to advance R&D efforts, it has entered into a scientific research collaboration agreement with Cinvestav, the Center for Research and Advanced Studies of the National Polytechnic Institute of Mexico (Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional) (https://ibn.fm/8UnHo). 

Cinvestav is a high-ranked, leading Mexican multidisciplinary scientific research institute that will work with Green Hygienics in R&D efforts to develop cannabinoid-based products targeting the endocannabinoid system (“ECS”) deficiencies in animals and humans. Cinvestav ranks fourth among Latin American research centers and 118th worldwide.

Green Hygienics is also launching TruLife Biotech, LLC. to advance studies in hemp-derived cannabinoid therapies, like the research conducted with Cinvestav. The focus of TruLife Biotech will be the development and advancement of innovative cannabinoid-based nutraceuticals, skincare products, and wellness brands addressing the ECS deficiencies in humans (https://ibn.fm/rCXOQ). 

“This research collaboration will be our first project under TruLife Biotech LLC, a Green Hygienics Company focused on the development and advancement of innovative cannabinoid-based nutraceutical and skincare products and brands,” Chief Scientific Officer Dr. Levan Darjania said. “The collaboration with Cinvestav will augment ongoing efforts by both parties to identify and explore selected cannabinoids and terpenes in planned combinations that may act synergistically to protect against pain development and determine their potential efficacy as pain relievers against inflammatory and neuropathic pain.” 

It is the collaborative model that Green Hygienics and Cinvestav will develop that will be used to create proprietary and effective products. “Discovery and development of cannabinoid-based products that are truly effective in producing the desired result are global tasks that are based on multidisciplinary approaches, collaborations, and partnerships. After meeting with leading researchers at Cinvestav’s Mexico City Campus, we are confident in our collaboration on the development of new and efficacious products,” COO Kyle MacKinnon added.

Even though the interaction of hemp-derived cannabinoids and the body’s ECS has been studied for the last 20 years, there is only pre-clinical data available. Still, the question that arises is how much of that data is genuine and useful. The company intends to use the new collaboration and TruLife Biotech formation to help answer these questions and develop the products necessary for ECS deficiencies, according to Dr. Darjania.

To further support the initiative, Green Hygienics has published a White Paper through Nutritional Outlook, an MJH Life Sciences(TM) brand that provides intelligent, well-informed insights and industry updates critical to the manufacturers of dietary supplements, health foods, and nutritional beverages.

The White Paper examines the therapeutic potential for cannabinoid health- and wellness-based products, but underlines the need to develop defined, consistent, and targeted products with established standards. The ultimate goal is to develop and promote scientific evidence-based ECS-modulating cannabinoid products that will be trusted by medical communities, physicians, holistic health practitioners, and wellness-oriented end users (https://ibn.fm/9929I). 

According to Dr. Darjania, Green Hygienics remains committed to changing the landscape of the industry and continuing the advancement of its hemp-derived cannabinoid phyto-remedy platform, with TruLife serving as a hub of biotechnology innovations and ultimately securing a strategic advantage in the market by introducing novel cannabinoids and biodelivery methods. These steps will help cement Green Hygienics’ role in the global hemp market, which was valued at $5.66 billion worldwide in 2020. The market is expected to grow at a CAGR of 25.17% from 2021 to 2028, resulting in an estimated value of $27.72 billion by 2028 (https://ibn.fm/mZEGs) and multiple expansion opportunities for Green Hygienics and its portfolio.

For more information, visit the company’s website at www.GreenHygienics.com.

NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://ibn.fm/GRYN

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.